Skip to main content
Equibles
MGRX logo

MGRX · Mangoceuticals, Inc. · Metrics

Track MGRX — free

Use MGRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MGRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.30 +0.02 (+7.14%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the 12 months from the date of issuance of this filing.”
View the 10-Q filed Aug 13, 2026
Market Cap
$6.04M
Shares
21.57M
Volume · Oct 20 172.71K Avg daily vol (3M) 12.64M

MGRX metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.30
Market cap
$6.04M

Price action

20 metrics
Price change (1W)
-26.9%
Price change (30D)
-37.8%
Price change (3M)
-33.5%
Price change (6M)
-45.1%
Price change (YTD)
-62.1%
Price change (1Y)
-88.3%
Trailing year
Price change (5Y)
—
52-week high
$2.74
52-week low
$0.16
Change from 52-week high
-89.8%
Change from 52-week low
+72.9%
Annualized volatility
215.5%
Annualized volatility (3M)
237.4%
Beta
1.4
RSI (14D)
31.6
Price vs SMA 50
-34.2%
Price vs SMA 200
-35.3%
Avg volume (3M)
12.64M
Relative volume
0.1
Average dollar volume
$6.47M

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
21.57M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
19.8×
reciprocal yield 5.0%
P / book
0.5
reciprocal yield 200.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-241.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
54.4%
Operating margin
-3,916.8%
Trailing 12 months
Net margin
-4,791.3%
Gross profit (TTM)
$171,590
Operating profit (TTM)
−$12.35M
Net income (TTM)
−$15.10M
Trailing 12 months
Diluted EPS (TTM)
$-0.79
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.96

Growth

11 metrics
Revenue growth YoY
-59.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$315,227
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+71.5%
Year over year · more shares
Revenue CAGR (3Y)
+270.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-120.6%
Return on assets
-106.6%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$19.06M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$228,688
Latest balance sheet
Cash & equivalents
$228,688
Total assets
$14.17M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.89M
Capital expenditures (TTM)
$3,519
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$2.17M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
0
Institutional ownership
5.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.3%
Private-fund adviser ownership
3.0%
Active holders' share change QoQ
+109.1%
Holder tenure
2.8
Price vs estimated holder cost
-57.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.2%

Short interest

3 metrics
Short interest
2.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
36 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1938046 CUSIP 56270V205 13F (30d) 2 filings 2 filers Visit website Investor relations